Literature DB >> 8084381

Blockade of neurotensin binding in the rat hypothalamus and of the central action of neurotensin on the hypothalamic-pituitary-adrenal axis with non-peptide receptor antagonists.

A Nicot1, A Bérod, D Gully, W Rowe, R Quirion, E R de Kloet, W Rostène.   

Abstract

Central administration of neurotensin (NT) has been shown to activate the hypothalamic-pituitary-adrenal axis, an effect which seems dependent upon the release of corticotropin-releasing factor. In this study, we describe the distribution of NT binding sites in the hypothalamus using film and emulsion receptor autoradiography. Among the 125I-NT-labelled hypothalamic nuclei, relatively high densities of neurotensin binding sites were detected over the paraventricular nucleus. Silver grains on emulsion-coated slides overlaid indiscriminately cell bodies and surrounding processes of magnocellular and parvocellular parts of the nucleus. Two newly developed NT receptor antagonists, SR 48692 and its analog SR 48450, competed for 125I-NT binding to hypothalamic tissue sections and membrane preparations with Ki values in the nanomolar range. Moreover, intracerebrally injected SR 48450 was able to block the NT-induced hypothalamic-pituitary-adrenal axis activation in freely moving rats, whereas its administration alone did not significantly affect basal plasma levels of adrenocorticotropin and corticosterone. These data provide anatomical substrate for a potential neurotensin action at the hypothalamus in the hypothalamic-pituitary-adrenal axis activation and highlight the use of new non-peptide NT receptor antagonists to characterize the effects of NT on neuroendrocrine functions.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8084381     DOI: 10.1159/000126707

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  7 in total

Review 1.  Neurotensin agonists: potential in the treatment of schizophrenia.

Authors:  Mona Boules; Amanda Shaw; Paul Fredrickson; Elliott Richelson
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

2.  A neurotensin antagonist, SR 48692, inhibits colonic responses to immobilization stress in rats.

Authors:  I Castagliuolo; S E Leeman; E Bartolak-Suki; S Nikulasson; B Qiu; R E Carraway; C Pothoulakis
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-29       Impact factor: 11.205

3.  Role of endogenous neurotensin in the behavioral and neuroendocrine effects of cocaine.

Authors:  C Betancur; R Cabrera; E R de Kloet; D Pélaprat; W Rostène
Journal:  Neuropsychopharmacology       Date:  1998-10       Impact factor: 7.853

4.  Characterization and distribution of binding sites for a new neurotensin receptor antagonist ligand, [3H]SR 48692, in the guinea pig brain.

Authors:  C Betancur; M Canton; D Gully; G Vela; D Pélaprat; W Rostène
Journal:  J Pharmacol Exp Ther       Date:  1995-06       Impact factor: 4.030

Review 5.  Neurotensin receptors: binding properties, transduction pathways, and structure.

Authors:  J P Vincent
Journal:  Cell Mol Neurobiol       Date:  1995-10       Impact factor: 5.046

Review 6.  In Search of Concomitant Alterations of Dopaminergic and Neurotensinergic Systems in Stress Conditions.

Authors:  Georgina Rodríguez de Lores Arnaiz; Marta C Antonelli
Journal:  Neurochem Res       Date:  2016-02-11       Impact factor: 3.996

7.  Selection for stress-induced analgesia affects the mouse hippocampal transcriptome.

Authors:  Pawel Lisowski; Adrian M Stankiewicz; Joanna Goscik; Marek Wieczorek; Lech Zwierzchowski; Artur H Swiergiel
Journal:  J Mol Neurosci       Date:  2011-12-16       Impact factor: 3.444

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.